EP3993873A4 - Suppression du virus de tumeur mammaire - Google Patents

Suppression du virus de tumeur mammaire Download PDF

Info

Publication number
EP3993873A4
EP3993873A4 EP20834735.1A EP20834735A EP3993873A4 EP 3993873 A4 EP3993873 A4 EP 3993873A4 EP 20834735 A EP20834735 A EP 20834735A EP 3993873 A4 EP3993873 A4 EP 3993873A4
Authority
EP
European Patent Office
Prior art keywords
mammary tumor
tumor virus
virus suppression
suppression
mammary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20834735.1A
Other languages
German (de)
English (en)
Other versions
EP3993873A1 (fr
Inventor
Sophie Bartsich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virago Vax Inc
Original Assignee
Virago Vax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/460,295 external-priority patent/US12029783B2/en
Application filed by Virago Vax Inc filed Critical Virago Vax Inc
Publication of EP3993873A1 publication Critical patent/EP3993873A1/fr
Publication of EP3993873A4 publication Critical patent/EP3993873A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/12011—Betaretrovirus, e.g. mouse mammary tumour virus
    • C12N2740/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/12011—Betaretrovirus, e.g. mouse mammary tumour virus
    • C12N2740/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP20834735.1A 2019-07-02 2020-07-02 Suppression du virus de tumeur mammaire Pending EP3993873A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/460,295 US12029783B2 (en) 2019-07-02 2019-07-02 Mammary tumor virus vaccine
US201962934858P 2019-11-13 2019-11-13
PCT/US2020/040742 WO2021003421A1 (fr) 2019-07-02 2020-07-02 Suppression du virus de tumeur mammaire

Publications (2)

Publication Number Publication Date
EP3993873A1 EP3993873A1 (fr) 2022-05-11
EP3993873A4 true EP3993873A4 (fr) 2023-09-20

Family

ID=74100827

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20834735.1A Pending EP3993873A4 (fr) 2019-07-02 2020-07-02 Suppression du virus de tumeur mammaire

Country Status (3)

Country Link
EP (1) EP3993873A4 (fr)
CA (1) CA3145293A1 (fr)
WO (1) WO2021003421A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12016844B2 (en) 2019-07-02 2024-06-25 Virago Vax Inc. Mammary tumor virus suppression

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090081220A1 (en) * 2004-01-29 2009-03-26 Jacob Hochman Method for diagnosing and treatment of breast cancer and pharmaceuticals composition and kit for same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2328181A1 (fr) * 1998-04-08 1999-10-14 International Bioimmune Systems, Inc. Compositions immunomodulatoires d'antigenes mmtv et leurs techniques d'application
EP1732569B1 (fr) * 2004-01-21 2009-10-14 Gilead Sciences, Inc. Utilisation d'adefovir ou de tenofovir pour inhiber les virus semblables a mmtv impliques dans le cancer du sein et la cirrhose biliaire primaire
WO2010135690A1 (fr) * 2009-05-21 2010-11-25 The Regents Of The University Of Michigan Traitement antiviral du lymphome et du cancer
US9383367B1 (en) * 2010-12-07 2016-07-05 Chunli Liu Methods of detecting conjugation site-specific and hidden epitope/antigen
WO2017147078A1 (fr) * 2016-02-22 2017-08-31 Brigham Young University Méthode et compositions pour le traitement de l'anémie par inhibition de furine
US12029783B2 (en) * 2019-07-02 2024-07-09 Virago Vax Inc. Mammary tumor virus vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090081220A1 (en) * 2004-01-29 2009-03-26 Jacob Hochman Method for diagnosing and treatment of breast cancer and pharmaceuticals composition and kit for same

Also Published As

Publication number Publication date
WO2021003421A1 (fr) 2021-01-07
EP3993873A1 (fr) 2022-05-11
CA3145293A1 (fr) 2021-01-07

Similar Documents

Publication Publication Date Title
EP4125973A4 (fr) Vaccinothérapie avec des néo-antigènes
EP3996744A4 (fr) Thérapie par vecteurs viraux
EP3849745A4 (fr) Pince
GB201910651D0 (en) Virus-like particle
EP3875119A4 (fr) Virus oncolytique pour le traitement du cancer
EP4028941A4 (fr) Configuration de propriété adaptée aux visiteurs
EP3996743A4 (fr) Virus de la vaccine manipulé
EP3985177A4 (fr) Bateau de travail de dragage
EP3993873A4 (fr) Suppression du virus de tumeur mammaire
EP4029418A4 (fr) Appareil de cuisson
EP3947742A4 (fr) Stratification du risque de cancers associés à un virus
EP3869916A4 (fr) Cuiseur
EP3797713A4 (fr) Dispositif de ligature
AU2019903260A0 (en) Cancer vaccine
AU2019903094A0 (en) Bio-printed kidney tissue
HK40087816A (en) Neoantigen vaccine therapy
HK40074725A (en) Virtual fiducials
HK40076156A (en) Viral vector therapy
AU2019901876A0 (en) Cancer vaccines
HK40072816A (en) Combination therapy
HK40071721A (en) Cancer treatment
HK40070244A (en) Cancer treatment
EP3928018A4 (fr) Bride
AU2019903026A0 (en) Cooker
AU2019902518A0 (en) Immuno-oncology therapy

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220131

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230818

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/21 20060101ALI20230811BHEP

Ipc: A61P 31/12 20060101ALI20230811BHEP

Ipc: A61P 31/14 20060101AFI20230811BHEP